Ultimovacs Announces Poster Presentation at the 2024
NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer ...
Read moreNON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer ...
Read moreOslo, April 15, 2024: In connection with the Annual General Meeting of Ultimovacs ASA to be held on April 18, ...
Read moreNON-REGULATORY PRESS RELEASE Oslo, April 9, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage ...
Read moreNON-REGULATORY PRESS RELEASE The NIPU trial is investigating the effect of adding UV1 vaccine to immunotherapy as second-line treatment of ...
Read moreReadout of topline result expected in March 2024 from UV1 randomized Phase II trial INITIUM in Ultimovacs’ lead indication, advanced ...
Read moreStudy protocol enables readout of the INITIUM trial after all patients have been followed for a minimum of 18 months, ...
Read moreOslo, 13 November 2023, Ultimovacs ASA (the "Company") refers to the announcement published on 9 November 2023 regarding the issuance ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.